Answers are grounded in this paper and cite their sources.
made in recent years and established evidence, suggesting elements of discussion in areas where evidence is still lacking and reviewing challenges that remain. In this issue, Poletti et al. [13] review the current diagnostic approach of IPF and further discuss the heterogeneity of the disease that encompasses various clinical presentations, complications, comorbidities and phenotypes, especially regarding familial pulmonary fibrosis, rapidly progressing disease and subclinical ‘early’ IPF, with each of them raising specific challenges for clinicians. They further critically review elements on which to discuss the indication for lung biopsy, the potential future role for cryobiopsies (a novel endoscopic technique that is currently under evaluation for diagnosing the usual interstitial pneumonia pattern), evaluation of individual prognosis in clinical practice, and the controversial issue of possible IPF and its practical management. In the next article of the series, Antoniou and Wells [in preparation] will review the current knowledge on acute exacerbations of IPF, a dreadful complication, which warrants active biologic and clinical research [14– 19] . Hypotheses for etiology, a proposed approach for appropriate diagnosis and suggested management will be reviewed, as well as recently identified potential triggers such as viral infection, surgery, microaspiration, expoIdiopathic pulmonary fibrosis (IPF) is a devastating disease, with a median survival from diagnosis of only 3 years [1] . Although it is a rare and somewhat orphan disease [2] , its incidence, prevalence and specific mortality are rising [3–6] , further increasing the many challenges faced by both patients and chest physicians. Recent evidence-based recommendations have been produced jointly by the American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society and the Latin American Thoracic Association, establishing standards for the diagnosis and management of IPF. Standardization of diagnosis criteria originally published in 2000 [7] and updated in 2011 [8] has set the stage for drug development, and one first drug (pirfenidone) has been approved in a number of countries, representing a significant achievement in the fight against IPF. However, IPF remains a diagnostic and therapeutic challenge [9–11] , with often more questions raised than answers provided. Clinicians also face a number of practical situations and decisions that are not fully addressed by international guidelines [9, 12] . This issue of Respiration includes the first article of a thematic review series on Practical issues and challenges in IPF ( table 1 ). This timely series authored by IPF experts will address selected practical issues, reviewing progress Published online: June 26, 2013
No takes yet. Share an insight, caveat, or question.
Cottin et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: